It is the protein targeted by alemtuzumab, a monoclonal antibody used for the treatment of chronic lymphocytic leukemia. A phase III trial into treatment of relapsing-remitting multiple sclerosis showed a reduction in relapse rate, but no statistically significant reduction in accumulated disability, when used as a first-line therapy.
It is the protein targeted by alemtuzumab, a monoclonal antibody utilized in the treatment of chronic lymphocytic leukemia. A phase III study on relapsing-remitting multiple sclerosis treatment demonstrated a decrease in relapse frequency, but no statistically significant reduction in accumulated disability, when used as an initial therapy.